Origin Therapeutics Portfolio Company TripSitter Joins Forces with Reconscious Medical, Expands to 23 States

Vancouver, B.C. & Toronto, ONMarch 29, 2022Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”), an actively managed, psychedelic-focused investment issuer, is pleased to announce that its portfolio company, TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter”), has joined forces with Reconscious Medical Insight Systems, PBC dba (“Reconscious”).

TripSitter enables physician-directed treatment plans for safe, legal, evidence-based psychedelic medicine. The company now serves 23 states across the U.S. including Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky, Maine, Michigan, Minnesota, Mississippi, Montana, Nebraska, New Hampshire, North Dakota, Oklahoma, Tennessee, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.

“Reconscious Medical brings a wealth of experience to the medical, clinical, operational, and administrative areas of TripSitter,” said Alexander Somjen, CEO of Origin Therapeutics. “This collaboration will enable the company to expand more rapidly while maintaining strict standards for patient safety, while also facilitating the opportunity for deep healing for its patients.”

Reconscious is a psychedelic psychotherapy company offering both in-clinic and virtual care. Its proprietary technology platform enables enhanced patient safety, monitoring, and support.

Four key members of the Reconscious team will join TripSitter, bringing significant psychedelics industry expertise to the team, and TripSitter’s current patient services will also be expanded to include additional services. The TripSitter Clinic technology platform will be updated to improve both the patient and practitioner experience, and will also soon offer both native iOS and Android apps.

“Reconscious’ primary focus and service to date has been combining psychedelic treatment with psychotherapy in both high and low doses of ketamine,” added Somjen. “This expertise will help TripSitter to continue setting the standard for at-home psychedelic treatment. First with ketamine, and with MDMA and psilocin to follow.”




About Origin Therapeutics

Origin Therapeutics Holdings Inc (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies. Learn more at www.originpsychedelics.com


For Further Information:

Alexander Somjen
Chief Executive Officer and Director
Origin Therapeutics Holdings Inc


For media inquiries, please contact: Brittany@Exvera.com

Cautionary Note

All information contained in this news release with respect to Microdose was supplied by Microdose for inclusion herein, and Origin’s directors and officers have relied on Microdose for such information.


Forward-Looking Information and Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.